NCT06876649 2026-03-02A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibEli Lilly and CompanyPhase 4 Recruiting787 enrolled
NCT07426484 2026-02-23Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyDana-Farber Cancer InstitutePhase 4 Not yet recruiting80 enrolled